Calcium and Inorganic Phosphorus Test in Delhi

Calcium & Inorganic Phosphorus Test at Home (Serum Calcium & Serum Phosphate)

The Calcium + Inorganic Phosphorus panel measures two of the body's most tightly regulated minerals, both governed by the same hormonal system and impossible to interpret meaningfully in isolation from each other. Together, they form the cornerstone of mineral metabolism assesyroid disorders, metabolic bone disease, and the mineral bone disease of chronic kidney disease (CKD-MBD).

Calcium and phosphorus exist in a reciprocal physiological relationship. When parathyroid hormone (PTH) rises, it increases serum calcium by mobilising bone and reducing renal calcium excretion, while simultaneously lowering serum phosphorus by increasing its renal clearance. When PTH is deficient or absent, calcium falls and phosphorus rises. When vitamin D is inadequate, both calcium and phosphorus absorption from the gut diminish. The direction and magnitude of change in both markers together is essential for distinguishing among the conditions that disrupt mineral homeostasis.

MAX@Home brings this investigation to your home. A certified phlebotomist visits at your scheduled time, collects blood using sterile technique, and samples are processed at a partner NABL-accredited laboratory with your digital report delivered within 24 to 48 hours.

What Serum Calcium Measures

Calcium is the most abundant mineral in the human body. Approximately 99 percent is stored in bone and teeth; about one percent circulates in the blood, maintained within 8.5 to 10.5 mg/dL through the integrated actions of PTH, calcitriol (active vitamin D), and calcitonin on bone, kidneys, and intestine.

Total serum calcium exists in three forms: albumin-bound calcium (approximately 40 percent), calcium complexed with anions such as citrate and bicarbonate (about 10 percent), and free ionised calcium (approximately 50 percent) - the biologically active fraction. Because calcium binds to albumin, total calcium can appear low in patients with hypoalbuminaemia even when ionised calcium is normal; a corrected calcium formula is applied.

The calcium–PTH feedback loop

The relationship between calcium and PTH is a classic negative feedback loop. When serum calcium falls below the normal range, calcium-sensing receptors on the parathyroid glands detect the change within seconds and trigger PTH release. PTH simultaneously mobilises bone calcium through osteoclast activation, increases renal tubular calcium reabsorption, and stimulates renal conversion of vitamin D to calcitriol - which in turn drives intestinal calcium absorption. The result is restoration of serum calcium toward the target range. Disruption at any point in this loop - the parathyroid glands, the kidneys, or vitamin D activation - causes measurable co-changes in both serum calcium and serum phosphorus.

What Serum Inorganic Phosphorus Measures

Phosphorus is the second most abundant mineral in the body after calcium, playing essential roles in bone mineralisation, cellular energy metabolism (as ATP), intracellular signalling pathways, and DNA and RNA structure. Approximately 85 percent is stored in bone, with the remainder distributed across cells and the blood compartment. Serum inorganic phosphorus (serum phosphate) is normally maintained between 2.5 and 4.5 mg/dL in adults.

Unlike calcium, serum phosphorus is less tightly regulated in the short term and shows greater daily variation with diet and time of day. Phosphorus levels tend to be lower in the morning fasting state and after carbohydrate-rich meals, which drive phosphate into cells alongside glucose. Specimens for phosphorus measurement are therefore best collected in the fasting state from a resting patient.

Hormonal regulation of phosphorus

• PTH is the primary phosphaturic hormone: it promotes renal phosphate excretion. In hyperparathyroidism, elevated PTH drives serum phosphorus down.
• FGF-23 (fibroblast growth factor 23), produced by bone osteocytes, is a second phosphaturic hormone that also suppresses renal vitamin D activation. FGF-23 becomes clinically important in CKD and X-linked hypophosphataemia.
• Calcitriol (active vitamin D) promotes both calcium and phosphorus absorption from the gut, raising serum levels of both.
• In CKD, failing kidneys cannot excrete phosphate normally, and serum phosphorus rises progressively as kidney function declines through the disease stages.

Calcium-phosphorus product in CKD

In patients with CKD, clinicians calculate the calcium-phosphorus product (Ca × P in mg/dL × mg/dL). When this product exceeds 55 mg²/dL², the risk of calcium phosphate precipitation in blood vessel walls, heart valves, and soft tissues rises significantly. This vascular calcification is a major driver of the dramatically elevated cardiovascular mortality in CKD. Keeping both calcium and phosphorus within target ranges through dietary phosphate restriction, phosphate binders, and careful vitamin D management is a central CKD treatment goal, and this panel is the monitoring tool used at every clinical review.

Why Test Calcium and Phosphorus Together

Measuring calcium and phosphorus in the same panel is essential because:

• The combination reveals the direction of the hormonal disturbance. High calcium + low phosphorus = PTH excess (hyperparathyroidism or PTHrP-driven hypercalcaemia of malignancy). Low calcium + high phosphorus = PTH deficiency (hypoparathyroidism) or advanced renal failure. Low calcium + low phosphorus = vitamin D deficiency with secondary hyperparathyroidism causing phosphaturia, or malabsorption.
• Interpreting either marker alone is diagnostically incomplete. Low calcium could be hypoparathyroidism or vitamin D deficiency - the phosphorus level distinguishes them. High phosphorus could be renal failure or hypoparathyroidism - the calcium level separates them.
• In CKD management, both values are required simultaneously to calculate the calcium-phosphorus product that guides phosphate binder selection and activated vitamin D dosing.
• The combination forms the core laboratory panel for CKD-MBD assessment alongside PTH, vitamin D, and ALP - and guides decisions on phosphate binders, calcimimetics, and active vitamin D analogues.

Pattern recognition across the four calcium-phosphorus combinations

Skilled clinicians read the calcium + phosphorus result as a diagnostic pattern. High Ca, Low P points toward primary hyperparathyroidism or humoral hypercalcaemia of malignancy. Low Ca, High P points toward hypoparathyroidism or advanced CKD. Low Ca, Low P points toward severe vitamin D deficiency with secondary hyperparathyroidism causing phosphaturia, or malabsorption with nutritional deficiency. High Ca, High P points toward vitamin D toxicity, milk-alkali syndrome, or immobilisation hypercalcaemia with concurrent renal failure. Each pattern generates a specific differential diagnosis that PTH and vitamin D measurements then refine.

Conditions This Panel Evaluates

Primary Hyperparathyroidism

Primary hyperparathyroidism is the most common cause of hypercalcaemia in outpatients and is often discovered incidentally. It results from autonomous PTH overproduction by one or more abnormal parathyroid glands - most commonly a single benign adenoma. The characteristic pattern is elevated calcium with low-to-normal phosphorus. Many patients are asymptomatic at discovery; others present with nephrolithiasis, bone pain, fatigue, and depression. Parathyroid surgery is the definitive treatment.

Hypoparathyroidism

Hypoparathyroidism produces the biochemically opposite pattern: low calcium with elevated phosphorus. The most common cause is surgical damage to the parathyroid glands during thyroid surgery. Autoimmune hypoparathyroidism is the next most frequent. Symptoms include perioral and peripheral tingling, muscle cramps, carpopedal spasm, and in severe cases laryngospasm and seizures. Treatment involves calcium supplements and activated vitamin D.

Chronic Kidney Disease - Mineral Bone Disease (CKD-MBD)

As renal function declines in CKD, phosphate excretion becomes progressively impaired, causing hyperphosphataemia. Reduced vitamin D activation in diseased kidneys leads to hypocalcaemia. Secondary hyperparathyroidism - the body's compensatory response - drives bone resorption, reduces bone density, and promotes vascular calcification. This panel is among the most frequently ordered investigations in CKD patients at every clinical review, forming the basis of treatment decisions about phosphate binders, calcimimetics, and active vitamin D analogues.

Metabolic Bone Disease - Rickets and Osteomalacia

Severe nutritional vitamin D deficiency causes secondary hyperparathyroidism that initially lowers phosphorus and may lower calcium in advanced cases, impairing bone mineralisation. This produces rickets in children and osteomalacia in adults - characterised by bone pain, proximal muscle weakness, and fractures disproportionate to bone density. The calcium + phosphorus pattern, combined with ALP, PTH, and 25-OH-D, establishes the diagnosis and guides nutritional repletion.

Pseudohypoparathyroidism

Pseudohypoparathyroidism is a rare genetic condition in which the kidneys and bone are resistant to PTH rather than PTH itself being absent. The biochemical pattern - low calcium and high phosphorus - is identical to true hypoparathyroidism, but PTH levels are markedly elevated rather than low. The calcium + phosphorus combination raises the diagnostic question; PTH measurement then distinguishes the two conditions.

Post-Thyroidectomy Monitoring

Thyroid surgery carries a risk of inadvertent damage to or removal of one or more parathyroid glands. Post-thyroidectomy monitoring of calcium and phosphorus detects hypoparathyroidism early - when calcium starts to fall and phosphorus to rise - enabling prompt supplementation with calcium and activated vitamin D before symptoms become severe or dangerous.

Who Should Get This Test

• Patients with CKD at any stage, for routine mineral bone disease surveillance and treatment monitoring.
• Individuals with symptoms of hypocalcaemia: muscle cramps, numbness, tingling, or tetany.
• Patients with known or suspected hyperparathyroidism requiring diagnostic workup or treatment monitoring.
• Those with bone pain, fractures, or reduced bone density being evaluated for metabolic bone disease.
• Children with features of rickets and adults with features of osteomalacia.
• Patients after thyroid or parathyroid surgery requiring post-operative calcium and phosphorus monitoring.
• Individuals with malabsorption conditions affecting mineral metabolism.

How to Prepare for the Test

Fasting requirements

An eight-to-ten hour fast before the test is recommended. Serum phosphorus is particularly sensitive to recent carbohydrate intake, which drives phosphate into cells transiently. Collecting fasting specimens ensures the result reflects the true steady-state phosphate level. Calcium is less affected by recent food intake but is also best measured under consistent fasting conditions for serial comparability.

Practical considerations

• Do not take calcium supplements on the morning of the test before the blood draw.
• Inform your doctor of all medications: calcium supplements, aluminium-containing antacids or phosphate binders (which lower serum phosphorus), thiazide diuretics (which raise calcium), and corticosteroids.
• For CKD patients, confirm with your nephrologist whether additional co-ordered markers such as PTH, ALP, or vitamin D should be collected in the same home visit.

How to Book with MAX@Home

MAX@Home makes booking a home blood test simple and efficient.

1.  Visit the MAX@Home website or call the helpline and select the Calcium + Inorganic Phosphorus panel.

2.  Schedule a morning fasting appointment at a time that fits your schedule.

3.  A certified phlebotomist arrives at your home with all necessary collection equipment.

4.  A single blood draw is collected and transported to a partner NABL-accredited laboratory.

5.  Your digital authenticated report is available within 24 to 48 hours, delivered to your registered contact details.